Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Molineaux Christopher
 2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2014		 3. Issuer Name and Ticker or Trading Symbol
Calithera Biosciences, Inc. [CALA]
(Last)
(First)
(Middle)
C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD. #200		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SR. VP, DRUG DEVELOPMENT
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

SOUTH SAN FRANCISCO, CA 94080		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 106,962
I
By Trust (1)
Common Stock 11,000
I
By Spouse

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (2) 12/13/2021 Common Stock 19,649 $ 0.48 I By Spouse
Stock Option (Right to Buy)   (3) 06/12/2022 Common Stock 24,252 $ 0.48 I By Spouse
Stock Option (Right to Buy)   (4) 05/22/2023 Common Stock 45,405 $ 0.96 I By Spouse
Stock Option (Right to Buy)   (5) 12/16/2023 Common Stock 115,713 $ 2.64 I By Spouse
Stock Option (Right to Buy)   (6) 09/08/2024 Common Stock 63,716 $ 7.2 I By Spouse
Stock Option (Right to Buy)   (7) 05/22/2023 Common Stock 39,011 $ 0.96 D  
Stock Option (Right to Buy)   (8) 12/16/2023 Common Stock 34,033 $ 2.64 D  
Stock Option (Right to Buy)   (9) 09/08/2024 Common Stock 18,740 $ 7.2 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Molineaux Christopher
C/O CALITHERA BIOSCIENCES, INC.
343 OYSTER POINT BLVD. #200
SOUTH SAN FRANCISCO, CA 94080		       SR. VP, DRUG DEVELOPMENT  

Signatures

/s/ Christopher J. Molineaux 10/01/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Shares and shares issuable pursuant to stock options, as applicable, are held by Molineaux Family Trust Dated Nov. 9, 2000, of which Reporting Person is a Trustee.
(2) 1/48 of the Option vests in equal monthly installments one month from 11/07/2011. The option shall be subject to accelerated vesting as set forth in such optionee's employment agreement with the Company.
(3) 1/48 of the Option vests in equal monthly installments one month from 03/27/2013. The option shall be subject to accelerated vesting as set forth in such optionee's employment agreement with the Company.
(4) 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in such optionee's employment agreement with the Company.
(5) 1/48 of the Option vests in equal monthly installments one month from 09/09/2014. The option shall be subject to accelerated vesting as set forth in such optionee's employment agreement with the Company.
(6) 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in such optionee's employment agreement with the Company.
(7) 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
(8) 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
(9) 1/48 of the Option vests in equal monthly installments one month from 09/09/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.